|
BR112017011914A2
(pt)
|
2014-12-05 |
2018-02-27 |
Memorial Sloan-Kettering Cancer Center |
?antígeno de maturação de célula b de direcionamento de anticorpos e métodos de uso?
|
|
WO2016090320A1
(en)
*
|
2014-12-05 |
2016-06-09 |
Memorial Sloan-Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
|
KR20180029201A
(ko)
|
2015-05-18 |
2018-03-20 |
티씨알2 테라퓨틱스 인크. |
융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법
|
|
IL295398B2
(en)
|
2015-10-23 |
2025-01-01 |
Eureka Therapeutics Inc |
Antibody/T-cell receptor chimeric constructs and their uses
|
|
US20170233484A1
(en)
|
2016-02-17 |
2017-08-17 |
Seattle Genetics, Inc. |
Bcma antibodies and use of same to treat cancer and immunological disorders
|
|
JP7194022B2
(ja)
|
2016-05-20 |
2022-12-21 |
イーライ リリー アンド カンパニー |
Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法
|
|
EP3494138A1
(en)
|
2016-08-02 |
2019-06-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
IL292551B2
(en)
|
2016-10-07 |
2023-10-01 |
Tcr2 Therapeutics Inc |
Preparations and methods for reprogramming T-cell receptors using fusion proteins
|
|
WO2018098365A2
(en)
|
2016-11-22 |
2018-05-31 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2018102795A2
(en)
|
2016-12-02 |
2018-06-07 |
University Of Southern California |
Synthetic immune receptors and methods of use thereof
|
|
JP7280828B2
(ja)
|
2017-01-23 |
2023-05-24 |
クレージュ メディカル カンパニー，リミテッド |
Ｂｃｍａを標的とする抗体およびその使用
|
|
US20190375815A1
(en)
|
2017-01-31 |
2019-12-12 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
AU2018222749B2
(en)
|
2017-02-17 |
2024-04-18 |
Fred Hutchinson Cancer Center |
Combination therapies for treatment of BCMA-related cancers and autoimmune disorders
|
|
KR20250022233A
(ko)
|
2017-04-26 |
2025-02-14 |
유레카 쎄라퓨틱스, 인코포레이티드 |
키메라 활성화 수용체 및 키메라 자극 수용체를 발현하는 세포 및 그의 용도
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
AU2018263887B2
(en)
|
2017-05-01 |
2025-04-24 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and an immunomodulatory compound
|
|
WO2019012015A1
(en)
*
|
2017-07-12 |
2019-01-17 |
Iontas Limited |
POTASIC CHANNEL INHIBITORS
|
|
EP3664820B1
(en)
|
2017-08-09 |
2023-07-19 |
Juno Therapeutics, Inc. |
Methods for producing genetically engineered cell compositions and related compositions
|
|
WO2019032929A1
(en)
|
2017-08-09 |
2019-02-14 |
Juno Therapeutics, Inc. |
METHODS AND COMPOSITIONS FOR PREPARING GENETICALLY MODIFIED CELLS
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
EP3679370A1
(en)
|
2017-09-07 |
2020-07-15 |
Juno Therapeutics, Inc. |
Methods of identifying cellular attributes related to outcomes associated with cell therapy
|
|
CA3075717A1
(en)
|
2017-09-14 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
CN111107874A
(zh)
|
2017-09-14 |
2020-05-05 |
葛兰素史密斯克莱知识产权发展有限公司 |
用于癌症的组合治疗
|
|
CA3075714A1
(en)
|
2017-09-14 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
KR20200086278A
(ko)
|
2017-10-18 |
2020-07-16 |
노파르티스 아게 |
선택적 단백질 분해를 위한 조성물 및 방법
|
|
US12031975B2
(en)
|
2017-11-01 |
2024-07-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
WO2019089982A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
KR20200097253A
(ko)
|
2017-11-01 |
2020-08-18 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 조성물의 생산방법
|
|
EP3703750B1
(en)
|
2017-11-01 |
2024-12-04 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
|
|
CN111511370A
(zh)
|
2017-11-01 |
2020-08-07 |
朱诺治疗学股份有限公司 |
对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体
|
|
WO2019089848A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
|
US12258580B2
(en)
|
2017-11-01 |
2025-03-25 |
Juno Therapeutics, Inc. |
Process for generating therapeutic compositions of engineered cells
|
|
MA50564A
(fr)
|
2017-11-06 |
2020-09-16 |
Hutchinson Fred Cancer Res |
Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase
|
|
JP2021502979A
(ja)
|
2017-11-15 |
2021-02-04 |
ノバルティス アーゲー |
Ｂｃｍａターゲティングキメラ抗原受容体、ｃｄ１９ターゲティングキメラ抗原受容体及び併用療法
|
|
KR20200096253A
(ko)
|
2017-11-30 |
2020-08-11 |
노파르티스 아게 |
Bcma-표적화 키메라 항원 수용체, 및 이의 용도
|
|
WO2019109053A1
(en)
|
2017-12-01 |
2019-06-06 |
Juno Therapeutics, Inc. |
Methods for dosing and for modulation of genetically engineered cells
|
|
WO2019113556A1
(en)
|
2017-12-08 |
2019-06-13 |
Juno Therapeutics, Inc. |
Serum-free media formulation for culturing cells and methods of use thereof
|
|
AU2018379094B2
(en)
|
2017-12-08 |
2025-09-25 |
Juno Therapeutics, Inc. |
Phenotypic markers for cell therapy and related methods
|
|
MX2020005908A
(es)
|
2017-12-08 |
2020-10-07 |
Juno Therapeutics Inc |
Proceso para producir una composicion de celulas t modificadas.
|
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
|
WO2019139987A1
(en)
|
2018-01-09 |
2019-07-18 |
Elstar Therapeutics, Inc. |
Calreticulin binding constructs and engineered t cells for the treatment of diseases
|
|
US20210038659A1
(en)
|
2018-01-31 |
2021-02-11 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
CN116041516A
(zh)
*
|
2018-02-01 |
2023-05-02 |
信达生物制药(苏州)有限公司 |
全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
EP3774901A1
(en)
|
2018-03-26 |
2021-02-17 |
Sutro Biopharma, Inc. |
Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
UY38251A
(es)
|
2018-06-01 |
2019-12-31 |
Novartis Ag |
Moléculas de unión contra bcma y usos de las mismas
|
|
CN108642085A
(zh)
*
|
2018-06-11 |
2018-10-12 |
北京安斯晨睿生物科技有限公司 |
携带bcma突变抗原基因的重组腺相关病毒载体及其构建方法与应用
|
|
EP3777895A4
(en)
*
|
2018-06-26 |
2021-12-22 |
ABL Bio Inc. |
ANTI-BCMA ANTIBODIES AND ASSOCIATED USE
|
|
DE202019005887U1
(de)
|
2018-07-03 |
2023-06-14 |
Marengo Therapeutics, Inc. |
Anti-TCR-Antikörpermoleküle und Verwendungen davon
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
SMT202400102T1
(it)
|
2018-07-19 |
2024-05-14 |
Regeneron Pharma |
Recettori chimerici dell’antigene con specificità per bcma e loro usi
|
|
WO2020033916A1
(en)
|
2018-08-09 |
2020-02-13 |
Juno Therapeutics, Inc. |
Methods for assessing integrated nucleic acids
|
|
KR20210057730A
(ko)
|
2018-08-09 |
2021-05-21 |
주노 쎄러퓨티크스 인코퍼레이티드 |
조작 세포 및 이의 조성물 생성 방법
|
|
CN112639083A
(zh)
|
2018-08-31 |
2021-04-09 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
|
US20210171909A1
(en)
|
2018-08-31 |
2021-06-10 |
Novartis Ag |
Methods of making chimeric antigen receptor?expressing cells
|
|
CA3118191A1
(en)
|
2018-10-31 |
2020-05-07 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treating cancer
|
|
CA3117568A1
(en)
|
2018-10-31 |
2020-05-07 |
Juno Therapeutics Gmbh |
Methods for selection and stimulation of cells and apparatus for same
|
|
PE20211058A1
(es)
|
2018-11-01 |
2021-06-07 |
Juno Therapeutics Inc |
Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d)
|
|
EP3873943A2
(en)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
|
IL282886B2
(en)
|
2018-11-08 |
2025-07-01 |
Juno Therapeutics Inc |
Methods and combinations for T-cell therapy and modulation
|
|
KR20210117260A
(ko)
|
2018-11-30 |
2021-09-28 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법을 사용한 치료방법
|
|
AU2020226893B2
(en)
|
2019-02-21 |
2025-02-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
SG11202108955QA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Antibody molecules that bind to nkp30 and uses thereof
|
|
CA3126087A1
(en)
|
2019-02-25 |
2020-09-03 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
|
BR112021017537A2
(pt)
|
2019-03-05 |
2021-12-14 |
Nkarta Inc |
Receptores de antígeno quimérico dirigidos a cd19 e usos dos mesmos em imunoterapia
|
|
US20230074800A1
(en)
|
2019-03-21 |
2023-03-09 |
Novartis Ag |
Car-t cell therapies with enhanced efficacy
|
|
US20220168389A1
(en)
|
2019-04-12 |
2022-06-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
US20220251152A1
(en)
|
2019-04-24 |
2022-08-11 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
CA3136742A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
AU2020265741A1
(en)
|
2019-05-01 |
2021-11-25 |
Editas Medicine, Inc. |
Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
JP2022537700A
(ja)
|
2019-06-12 |
2022-08-29 |
ジュノー セラピューティクス インコーポレイテッド |
細胞媒介細胞傷害性療法と生存促進性ｂｃｌ２ファミリータンパク質の阻害剤との併用療法
|
|
EP4006055A4
(en)
*
|
2019-07-30 |
2023-07-19 |
Shanghai Hansoh Biomedical Co., Ltd. |
ANTI-BCMA ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF
|
|
US20220289859A1
(en)
|
2019-08-06 |
2022-09-15 |
Glaxosmithkline Intellectual Property Development Limited |
Biopharmacuetical Compositions and Related Methods
|
|
JP2022545467A
(ja)
|
2019-08-22 |
2022-10-27 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法
|
|
CN112574308A
(zh)
*
|
2019-09-30 |
2021-03-30 |
和铂医药(苏州)有限公司 |
靶向bcma的抗体、双特异性抗体及其用途
|
|
MX2022005145A
(es)
|
2019-10-30 |
2022-06-29 |
Juno Therapeutics Gmbh |
Dispositivos de estimulación y/o selección celular y método de uso.
|
|
WO2021092060A1
(en)
*
|
2019-11-05 |
2021-05-14 |
Engmab Sarl |
Methods of treatment
|
|
TW202134264A
(zh)
|
2019-11-26 |
2021-09-16 |
瑞士商諾華公司 |
嵌合抗原受體及其用途
|
|
US20230039487A1
(en)
*
|
2019-12-17 |
2023-02-09 |
Shenzhen Feipeng Biological Therapy Co. Ltd |
BCMA-binding antibody and use thereof
|
|
CN113061185B
(zh)
*
|
2020-01-02 |
2023-08-08 |
益科思特(北京)医药科技发展有限公司 |
一种bcma抗体的制备方法与应用
|
|
KR102837521B1
(ko)
*
|
2020-01-03 |
2025-07-22 |
바이오션, 인코포레이티드 |
Bcma에 결합하는 항체 및 이의 용도
|
|
CN116234829A
(zh)
|
2020-01-03 |
2023-06-06 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
KR20220012314A
(ko)
*
|
2020-01-03 |
2022-02-03 |
살루브리스 (청두) 바이오테크 코., 리미티드 |
Bcma에 결합하는 항체 및 그의 용도
|
|
JP2023512209A
(ja)
|
2020-01-28 |
2023-03-24 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞形質導入のための方法
|
|
KR20220152227A
(ko)
|
2020-02-12 |
2022-11-15 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｂｃｍａ-지시된 키메라 항원 수용체 ｔ 세포 조성물 및 이의 방법 및 용도
|
|
WO2021173985A2
(en)
|
2020-02-27 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
MX2022010685A
(es)
|
2020-02-27 |
2022-09-23 |
Novartis Ag |
Metodos de produccion de celulas que expresan receptores de antigeno quimericos.
|
|
AU2021251265A1
(en)
|
2020-04-10 |
2022-11-03 |
Juno Therapeutics, Inc. |
Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen
|
|
MX2022013530A
(es)
|
2020-04-28 |
2023-02-01 |
Juno Therapeutics Inc |
Combinación de terapia de células t dirigida a bcma y un compuesto inmunomodulador.
|
|
JP7727662B2
(ja)
|
2020-05-13 |
2025-08-21 |
ジュノー セラピューティクス インコーポレイテッド |
臨床応答に関連する特徴量の特定方法およびその使用
|
|
WO2021248005A1
(en)
|
2020-06-05 |
2021-12-09 |
Eisai R&D Management Co., Ltd. |
Anti-bcma antibody-drug conjugates and methods of use
|
|
EP4165169A1
(en)
|
2020-06-11 |
2023-04-19 |
Novartis AG |
Zbtb32 inhibitors and uses thereof
|
|
JP2023531531A
(ja)
|
2020-06-26 |
2023-07-24 |
ジュノ セラピューティクス ゲーエムベーハー |
組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
|
|
CA3188978A1
(en)
|
2020-08-21 |
2022-02-24 |
Sandeep Tharian Koshy |
Compositions and methods for in vivo generation of car expressing cells
|
|
WO2022098787A1
(en)
|
2020-11-04 |
2022-05-12 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
EP4301755A1
(en)
|
2021-03-03 |
2024-01-10 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and a dgk inhibitor
|
|
JP2024511420A
(ja)
|
2021-03-22 |
2024-03-13 |
ジュノー セラピューティクス インコーポレイテッド |
ウイルスベクター粒子の効力を評価する方法
|
|
EP4314814A1
(en)
|
2021-03-22 |
2024-02-07 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
|
CA3214757A1
(en)
|
2021-04-08 |
2022-10-13 |
Andreas Loew |
Multifuntional molecules binding to tcr and uses thereof
|
|
KR20230171468A
(ko)
|
2021-04-16 |
2023-12-20 |
셀진 코포레이션 |
Bcma-지시된 t 세포 요법과의 조합 요법
|
|
CA3214280A1
(en)
|
2021-04-16 |
2022-10-20 |
Julie Ann RYTLEWSKI |
T cell therapy in patients who have had prior stem cell transplant
|
|
AU2022267891A1
(en)
|
2021-04-27 |
2023-11-09 |
Novartis Ag |
Viral vector production system
|
|
KR20240004659A
(ko)
|
2021-04-30 |
2024-01-11 |
셀진 코포레이션 |
감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법
|
|
US20250283037A1
(en)
|
2021-05-06 |
2025-09-11 |
Juno Therapeutics Gmbh |
Methods for stimulating and transducing t cells
|
|
WO2022248870A1
(en)
|
2021-05-28 |
2022-12-01 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapies for treating cancer
|
|
CN113527477B
(zh)
*
|
2021-07-23 |
2023-05-23 |
河南农业大学 |
猪源抗PDCoV-N蛋白的scFv及其表达载体、构建方法和应用
|
|
KR20240040786A
(ko)
|
2021-08-03 |
2024-03-28 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
생물제약 조성물 및 안정한 동위원소 표지 펩티드 맵핑 방법
|
|
AR126838A1
(es)
|
2021-08-20 |
2023-11-22 |
Novartis Ag |
Métodos para preparar células que expresan receptores de antígeno quiméricos
|
|
JP2024537863A
(ja)
|
2021-10-05 |
2024-10-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
がんを処置するための組合せ療法
|
|
JP2024540320A
(ja)
|
2021-11-03 |
2024-10-31 |
セルジーン コーポレーション |
骨髄腫を処置する際に使用するための、ｂ細胞成熟抗原に特異的なキメラ抗原受容体
|
|
EP4469484A1
(en)
|
2022-01-25 |
2024-12-04 |
GlaxoSmithKline Intellectual Property Development Ltd |
Combination therapy for cancer
|
|
US20250101379A1
(en)
|
2022-01-28 |
2025-03-27 |
Juno Therapeutics, Inc. |
Methods of manufacturing cellular compositions
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
|
US20250302954A1
(en)
|
2022-05-11 |
2025-10-02 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
US20250345432A1
(en)
|
2022-05-25 |
2025-11-13 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
EP4532695A1
(en)
|
2022-05-25 |
2025-04-09 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
CA3263560A1
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics Inc |
GPRC5D AND BCMA SPECIFIC CHIMERICAL ANTIGENIC RECEPTORS
|
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
|
AU2023369684A1
(en)
|
2022-10-26 |
2025-04-17 |
Novartis Ag |
Lentiviral formulations
|
|
EP4611798A1
(en)
|
2022-11-02 |
2025-09-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
EP4611774A2
(en)
*
|
2022-11-04 |
2025-09-10 |
MiNK Therapeutics, Inc. |
B-cell maturation antigen (bcma) chimeric antigen receptor invariant natural killer t cells and uses thereof
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
CN120303298A
(zh)
|
2022-12-05 |
2025-07-11 |
葛兰素史密斯克莱知识产权发展有限公司 |
使用b细胞成熟抗原拮抗剂的治疗方法
|
|
EP4658675A1
(en)
|
2023-02-03 |
2025-12-10 |
C3S2 GmbH |
Methods for non-viral manufacturing of engineered immune cells
|
|
WO2024168192A1
(en)
|
2023-02-10 |
2024-08-15 |
Celgene Corporation |
Assessment of bcma in biological samples
|
|
WO2024220588A1
(en)
|
2023-04-18 |
2024-10-24 |
Juno Therapeutics, Inc. |
Cytotoxicity assay for assessing potency of therapeutic cell compositions
|
|
WO2024243365A2
(en)
|
2023-05-23 |
2024-11-28 |
Juno Therapeutics, Inc. |
Activation markers of t cells and method for assessing t cell activation
|
|
CN117069847B
(zh)
|
2023-10-08 |
2024-07-12 |
北京奇迈永华生物科技有限公司 |
靶向bcma抗体及其相关产品和医药用途
|
|
GB202317065D0
(en)
|
2023-11-07 |
2023-12-20 |
Coding Bio Ltd |
BCMA binding molecules
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
WO2025171388A1
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens with modified domains and related methods and uses
|
|
WO2025171383A2
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens and related methods and uses
|